Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease

References

• Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1(1):15018. doi:10.1038/nrdp.2015.18
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Sun L, Xie P, Liu F-Y, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011;6:395–423. doi:10.1146/annurev.pathol.4.110807.092150
   PubMed Web of Science ®Google Scholar
• Gilbert RE. Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease. Diabetes. 2017;66(4):791–800. doi:10.2337/db16-0796
   PubMed Web of Science ®Google Scholar
• de Vries APJ, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417–426. doi:10.1016/S2213-8587(14)70065-8
   PubMed Web of Science ®Google Scholar
• Huang Y, Sun Y, Cao Y, et al. HRD1 prevents apoptosis in renal tubular epithelial cells by mediating eIF2α ubiquitylation and degradation. Cell Death Dis. 2017;8(12):3202. doi:10.1038/s41419-017-0002-y
   PubMed Web of Science ®Google Scholar
• Lau GJ, Godin N, Maachi H, et al. Bcl-2-modifying factor induces renal proximal tubular cell apoptosis in diabetic mice. Diabetes. 2012;61(2):474–484. doi:10.2337/db11-0141
   PubMed Web of Science ®Google Scholar
• Yu SM-W, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. Adv Chronic Kidney Dis. 2018;25(2):166–180. doi:10.1053/j.ackd.2017.12.005
   PubMed Web of Science ®Google Scholar
• Puca F, Yu F, Bartolacci C, et al. Medium-chain Acyl-CoA dehydrogenase protects mitochondria from lipid peroxidation in glioblastoma. Cancer Discov. 2021;11(11):2904–2923. doi:10.1158/2159-8290.CD-20-1437
   PubMed Web of Science ®Google Scholar
• Dearlove OR, Perkins R. MCAD deficiency and anaesthesia. Anaesthesia. 1995;50(3):265. doi:10.1111/j.1365-2044.1995.tb04584.x
   PubMed Web of Science ®Google Scholar
• Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15–25. doi:10.1016/j.cmet.2004.12.003
   PubMed Web of Science ®Google Scholar
• Kumar A, Sundaram K, Teng Y, et al. Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance. Theranostics. 2022;12(3):1388–1403. doi:10.7150/thno.62514
   PubMedGoogle Scholar
• Declèves A-E, Zolkipli Z, Satriano J, et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 2014;85(3):611–623. doi:10.1038/ki.2013.462
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature. 2004;432(7020):1027–1032. doi:10.1038/nature03047
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shih DQ, Kuwajima S, Norris AW, Kahn CR, Stoffel M. Role of foxa-2 in adipocyte metabolism and differentiation. J Clin Invest. 2003;112(3):345–356. doi:10.1172/JCI18698
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Stoffel M. Coactivation of foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab. 2006;3:2. doi:10.1016/j.cmet.2006.01.001
   Web of Science ®Google Scholar
• Yokoyama Y, Iguchi K, Usui S, Hirano K. AMP-activated protein kinase modulates the gene expression of aquaporin 9 via forkhead box a2. Arch Biochem Biophys. 2011;515(1–2):80–88. doi:10.1016/j.abb.2011.08.002
   PubMed Web of Science ®Google Scholar
• Fiévet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol. 2009;20(6):505–511. doi:10.1097/MOL.0b013e328332e9ef
   PubMed Web of Science ®Google Scholar
• Ansquer J-C, Foucher C, Rattier S, Taskinen M-R, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45(3):485–493. doi:10.1053/j.ajkd.2004.11.004
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang X, Cheng R, Ma J-X, Yi J, Li J. Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation. Cell Tissue Res. 2019;376(2):165–177. doi:10.1007/s00441-018-2974-z
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang J, Guo W, et al. Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med. 2016;93:94–109. doi:10.1016/j.freeradbiomed.2016.02.002
   PubMed Web of Science ®Google Scholar
• Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities. Int J Mol Sci. 2020;21(7):2632. doi:10.3390/ijms21072632
   PubMed Web of Science ®Google Scholar
• Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21(1):37–46. doi:10.1038/nm.3762
   PubMed Web of Science ®Google Scholar
• Zeni L, Norden AGW, Cancarini G, Unwin RJ. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30(6):701–717. doi:10.1007/s40620-017-0423-9
   PubMed Web of Science ®Google Scholar
• Rodríguez-Vilarrupla A, Laviña B, García-Calderó H, et al. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J Hepatol. 2012;56(5):1033–1039. doi:10.1016/j.jhep.2011.12.008
   PubMed Web of Science ®Google Scholar
• Park CW, Zhang Y, Zhang X, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006;69(9):1511–1517. doi:10.1038/sj.ki.5000209
   PubMed Web of Science ®Google Scholar
• Sohn M, Kim K, Uddin MJ, et al. Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy. Am J Physiol Renal Physiol. 2017;312(2):F323–F334. doi:10.1152/ajprenal.00596.2015
   PubMed Web of Science ®Google Scholar
• Das Pradhan A, Glynn RJ, Fruchart J-C, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923–1934. doi:10.1056/NEJMoa2210645
   PubMed Web of Science ®Google Scholar
• Habib SL. Diabetes and renal tubular cell apoptosis. World J Diabetes. 2013;4(2):27–30. doi:10.4239/wjd.v4.i2.27
   PubMedGoogle Scholar
• Ohse T, Inagi R, Tanaka T, et al. Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells. Kidney Int. 2006;70(8):1447–1455. doi:10.1038/sj.ki.5001704
   PubMed Web of Science ®Google Scholar
• Liu X, Xu C, Xu L, et al. Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. Metabolism. 2020;111:154334. doi:10.1016/j.metabol.2020.154334
   PubMed Web of Science ®Google Scholar
• Song A, Zhang C, Meng X. Mechanism and application of metformin in kidney diseases: an update. Biomed Pharmacother. 2021;138:111454. doi:10.1016/j.biopha.2021.111454
   PubMed Web of Science ®Google Scholar
• Chen W-L, Chen Y-L, Chiang Y-M, Wang S-G, Lee H-M. Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway. Biochem Pharmacol. 2012;84(4):522–531. doi:10.1016/j.bcp.2012.05.022
   PubMed Web of Science ®Google Scholar
• Murakami H, Murakami R, Kambe F, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006;341(4):973–978. doi:10.1016/j.bbrc.2006.01.052
   PubMed Web of Science ®Google Scholar
• Kim J, Ahn J-H, Kim J-H, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res. 2007;84(5):886–893. doi:10.1016/j.exer.2007.01.009
   PubMed Web of Science ®Google Scholar
• Cerrada-Gimenez M, Tusa M, Casellas A, et al. Altered glucose-stimulated insulin secretion in a mouse line with activated polyamine catabolism. Transgenic Res. 2012;21(4):843–853. doi:10.1007/s11248-011-9579-6
   PubMed Web of Science ®Google Scholar